Objectives: Arginine deficiency may contribute to microvascular dysfunction, but previous studies suggest that arginine supplementation may be harmful in sepsis. Systemic arginine availability can be estimated by measuring the ratio of arginine to its endogenous inhibitors, asymmetric and symmetric dimethylarginine. We hypothesized that the arginine-to-dimethylarginine ratio is reduced in patients with severe sepsis and associated with severity of illness and outcomes.
M icrovascular dysfunction in severe sepsis and septic shock may result from reduced bioavailability of nitric oxide (NO) (1) . NO is produced by NO synthase (NOS), converting arginine to NO and citrulline. NO synthesis is inhibited by asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), which are metabolites of arginine produced during protein catabolism and catalyzed by protein arginine methyltransferase (2, 3) . SDMA inhibits NO synthesis by competitively inhibiting cellular arginine uptake via membrane cationic amino acid transporters (3, 4) , and ADMA inhibits NO synthesis primarily by direct competitive inhibition of NOS (2) . Arginine is also metabolized by arginase, producing urea and ornithine. Based on this biochemistry, systemic arginine availability has been estimated in cardiovascular and pulmonary diseases by calculating ratios of arginine to its enzymatic products (e.g., citrulline and ornithine) and by calculating ratios of arginine to its inhibitory metabolic byproducts (e.g., ADMA and SDMA) (5, 6) .
Previous studies have shown that arginine levels are low in sepsis, at least partly because of impaired endogenous arginine synthesis and accelerated hepatic arginine clearance (7) (8) (9) (10) . However, these studies did not specifically link arginine deficiency with poor outcome or severity of illness. ADMA levels are independently associated with mortality in unselected critically ill patients (11, 12) ; however, the relationship between ADMA and outcome, specifically in septic patients, has not been established (13) . Experimental studies show that low systemic arginine availability occurs after endotoxemia and also im-pairs vital organ blood flow and cardiovascular function (14, 15) .
It is unknown whether the aforementioned ratios have prognostic significance in severe sepsis and septic shock. The goal of this study was to determine whether these estimates of systemic arginine availability are reduced in patients with severe sepsis and septic shock and whether they are associated with severity of illness and outcomes. Some of the results of this study have been reported previously in abstract form (16) .
MATERIALS AND METHODS

Study Design
This was a prospective, single-center, cohort study described previously (17) . Consecutive patients meeting diagnostic criteria for severe sepsis or septic shock (18) (collectively referred to hereafter as severe sepsis) admitted to the medical or surgical intensive care units at the University of Rochester Medical Center were screened for enrollment. The comprehensive list of prospectively defined exclusion criteria are shown in Figure 1 .
Venous blood samples were collected within 48 hrs of diagnosis and again 3-5 days later. Patients were not enrolled if laboratory technicians were unavailable to process specimens within 48 hrs of diagnosis ( Fig. 1) . Whole blood was centrifuged at 1500 g for 10 mins and the plasma supernatant was immediately snap-frozen and stored at Ϫ80°C until analysis. Amino acids were measured using ion exchange chromatography, and dimethylarginines were measured using reversedphase high-performance liquid chromatography coupled with positive electron ion spray mass spectrometry in multiple reaction monitoring mode (see the complete description of laboratory measurements in the supplemental data [Supplemental Digital Content 1, http://links.lww.com/CCM/A233]). The ratios of arginine to its inhibitory dimethylarginine metabolites (DMAs; i.e., ADMA and SDMA) and of arginine to its enzymatic byproducts citrulline and ornithine [arginine/(citrulline ϩ ornithine)] were calculated to estimate systemic arginine availability. Arginase activity was estimated by the arginine-to-ornithine ratio (6) . To provide relevant reference ranges for our measurements, control subjects without acute illness were recruited from the local community by age and gender strata approximating the severe sepsis cohort. Control subjects were excluded if they had conditions or used medications shown in Figure 1 or if they had active infection or used antibiotics within 6 wks of sample collection. All subjects or their surrogates provided informed consent and the study protocol was approved by the University of Rochester Research Subjects Review Board.
In a post hoc analysis, we measured urinary nitrate concentrations in samples obtained simultaneously with the blood sample to assess relationships between estimates of systemic arginine availability and NO production. Urine nitrate was measured using reductive chemiluminescence (see description of laboratory measurements in the supplemental data [Supplemental Digital Content 1, http://links.lww.com/CCM/A233]). Urine nitrate concentrations were divided by the urine creatinine concentration measured using a commercially available colorimetric assay (R & D Systems, Minneapolis, MN) to adjust for urine dilution (19) . Results are expressed as M urine nitrate/mM urine creatinine. Values were not available in two septic subjects because one subject's urine specimen was lost and another subject's urine creatinine was below the lower detection limit.
Statistical Analyses
Results are expressed as mean Ϯ SD or median (interquartile range), as appropriate. Student's t test, the Wilcoxon rank-sum test, or the Wilcoxon matched pairs signed-ranks test was used to compare continuous or discrete variables between groups of subjects and between measurements from the same subjects at different times, as appropriate. The chi-square test was used to compare categorical variables.
Spearman's rank correlation coefficients () were calculated between arginine-to-DMA ratio or arginine/(citrulline ϩ ornithine) ratio and other continuous variables, including urinary nitrate concentrations, Acute Physiology and Chronic Health Evaluation II scores (using data from the first 24 hrs of intensive care unit admission), sepsis-related organ failure assessment scores, number of organ failurefree days from days 0 -28, and number of ven- tilator-free days from days 0 -28 (20 -22) . The Kaplan-Meier method was used to assess the relationship between arginine-to-DMA ratio or arginine/(citrulline ϩ ornithine) ratio and 6-month survival (23) .
Multivariable logistic regression was used to assess the independent associations between arginine-to-DMA or arginine/(citrulline ϩ ornithine) ratios and severe sepsis while controlling for potential confounding variables. Multivariable logistic regression and Cox proportional hazards analyses were used to assess the independent relationship between these ratios and hospital mortality or risk of death over the course of 6 months, 
RESULTS
From February 2006 through May of 2008, 430 patients with clinical suspicion for severe sepsis were screened and 109 patients were enrolled ( Fig. 1 ). Fifty agestratified and gender-stratified control sub-jects without acute illness were recruited. Clinical characteristics of the study subjects are shown in Table 1 . In severe sepsis subjects, the initial blood samples were obtained 30 (20 -39) hrs after diagnosis, and statistical analyses are based on these measurements unless otherwise specified. Thirty-one severe sepsis patients died during hospitalization: 25 (80%) during the initial sepsis episode, three (10%) during a recurrent sepsis episode, and three (10%) from cardiovascular causes after sepsis had clinically resolved.
Severe Sepsis Versus Control Subjects
Severe sepsis patients had lower arginine, citrulline, and ornithine levels and higher ADMA and SDMA levels than control subjects ( Table 2 ). Compared to control subjects, severe sepsis patients had lower arginine-to-DMA ratios ( Fig.  2A ) but similar arginine/(citrulline ϩ ornithine) and arginine-to-ornithine ratios ( Table 2 ). The arginine-to-DMA ratio was independently associated with sepsis after adjustment for baseline differences in creatinine and Charlson comorbidity score (24) between control and severe sepsis subjects (odds ratio, 5.91 per quartile decrease in arginineto-DMA ratio; 95% confidence interval, 2.45-14.26; p Ͻ .001; Table 3 ).
Relationship of Aginine-to-DMA and Arginine/(Citrulline ؉ Ornithine) Ratios to Clinical Outcomes and Severity of Illness in Severe Sepsis
Comparison of clinical variables between severe sepsis hospital survivors and nonsurvivors are shown in Table 1 . Hospital nonsurvivors had similar amino acid levels but higher dimethylarginine levels compared to survivors ( Table 2 ). The arginine-to-DMA ratio and, to a lesser extent, the arginine/(citrulline ϩ ornithine) ratio were reduced in nonsurvivors vs. survivors ( Table 2 and Fig. 2B ). The arginine-to-DMA ratio was negatively correlated with Acute Physiology and Chronic Health Evaluation II score (Spearman's ϭ Ϫ0.404; p Ͻ .001) and maximal sepsis-related organ failure assessment score from days 0 -7 (Spearman's ϭ Ϫ0.319; p Ͻ .001) and positively correlated with numbers of organ failurefree days (Spearman's ϭ 0.302; p ϭ .001) and ventilator-free days (Spearman's ϭ 0.262; p ϭ .006). These illness severity measures and outcomes were not signifi- Values are median (interquartile range), number (percentage), or mean (ϮSD); b organ dysfunctions as defined previously (48) with slight modification, including: cardiovascular (hypotension [systolic blood pressure] Ͻ90 mm Hg or mean arterial pressure Ͻ60 mm Hg, vasopressor requirement, or clinical evidence of hypoperfusion); acid base (metabolic acidosis and plasma lactate concentration 2 mmol/L); renal (urine output Ͻ0.5 mL/kg/hr despite fluid resuscitation); neurologic (altered mental status without other causes); respiratory (PaO 2 :FIO 2 ratio Ͻ250, or Ͻ200 if lungs are only dysfunctional organ); and hematologic (platelet count Ͻ80,000 or Ͼ50% decrease from baseline); c shock indicate hypotension or vasopressor dependence that persisted for Ն3 hrs despite fluid challenge.
cantly correlated with the arginine/(citrulline ϩ ornithine) or arginine-to-ornithine ratios.
In univariate analysis, the odds ratio of hospital death increased progressively with decreasing arginine-to-DMA ratio (odds ratio, 2.13 per quartile decline of arginine-to-DMA ratio; 95% confidence interval, 1.38 -3.29; p ϭ .001). Six-month survival also decreased as the arginine-to-DMA ratio declined (hazard ratio, 1.68 per quartile decline of arginine-to-DMA ratio; 95% confidence interval, 1.25-2.26; p ϭ .001; logrank test chi-square ϭ 13.72; p ϭ .003; Fig.  3 ). The arginine/(citrulline ϩ ornithine) ratio was associated with hospital mortality in univariate analysis [odds ratio, 1.47 per quartile decline in arginine(citrulline ϩ ornithine) ratio; 95% CI, 1.00 -2.16; p ϭ .049] but did not predict 6-month survival (hazard ratio, 1.26; 95% confidence interval, 0.95Ϫ1.67; p ϭ .105; log-rank test chi-square ϭ 2.89; p ϭ .41). The arginine-to-ornithine ratio was not associated with either hospital mortality or 6-month survival. Arg, arginine. a Values refer to median(interquartile range). Amino acid concentrations are micromolar, methylarginine concentrations are nanomolar, and methylarginine concentrations were converted to micromolar before calculation of the Arg/dimethylarginine ratio. The initial model also included presence or absence or preexisting hypertension, removed without significant deterioration in model fit as described in Methods; b these odds ratios and hazard ratios refer to a one-quartile change in the value of the covariate; c the initial model also included Charlson comorbidity score and presence or absence or preexisting hypertension. Both were removed without significant deterioration in model fit as described in Methods; d the initial model also included age and Charlson comorbidity score. Both were removed without significant deterioration in model fit as described in Methods.
Multivariable Analysis
Multivariable logistic regression showed that the arginine-to-DMA ratio was a significant independent predictor of hospital mortality (odds ratio, 1.63; 95% confidence interval, 1.00 -2.65 per quartile decrease in arginine-to-DMA ratio; p ϭ .048; Table 3 ) after controlling for baseline differences in age and creatinine concentration (see Table 1 for baseline differences between groups and the supplemental data [Supplemental Digital Content 1, http://links.lww.com/CCM/A233] for details of multivariable modeling). Likewise, multivariable Cox proportional hazards analysis showed that the arginine-to-DMA ratio was a significant independent predictor of the risk of death over the course of 6 months after con-trolling for a history of hypertension and creatinine concentration (hazard ratio, 1.41; 95% confidence interval, 1.01-1.98 per quartile decrease in arginine-to-DMA ratio; p ϭ .043; Table 3 ). The arginine-(citrulline ϩ ornithine) ratio was not an independent predictor of hospital mortality (odds ratio, 1.23 per quartile decrease in ratio; 95% confidence interval, 0.81-1.87; p ϭ .330) after controlling for age and creatinine in the final model.
Relationship Between Arginineto-DMA Ratio and Urinary Nitrate Concentrations
Urinary nitrate concentrations were significantly higher in controls (92.8 M nitrate/mM creatinine; interquartile range, 68.0 -151.2) vs. sepsis patients (24.9 M nitrate/mM creatinine; interquartile range, 6.6 -67.0; p Ͻ .001) and nonsignificantly higher in sepsis survivors (30.8 M nitrate/mM creatinine; interquartile range, 9.2-82.5) vs. nonsurvivors (16.5 M nitrate/mM creatinine; interquartile range, 5.4 -54.1; p ϭ .077). Analyzing all paired plasma and urine measurements (n ϭ 157), the arginineto-DMA ratio was directly correlated with urinary nitrate concentration (Spearman's ϭ 0.449; p Ͻ .001; see Figure E2 in the supplemental data [Supplemental Digital Content 1, http://links.lww.com/CCM/A233]). This significant correlation was not evident, however, when separately analyzing the severe sepsis cases (Spearman's ϭ 0.132; p ϭ .174) or the control subjects (Spearman's ϭ Ϫ0.179; p ϭ .214).
Subsequent Measurements
Ninety-one sepsis subjects had repeat plasma samples (measurement 2) obtained 67 (48 -72) hrs after the initial measurements and 90 (79 -110) hrs after diagnosis. Eighteen subjects did not have repeat measurements because of death (n ϭ 10), insufficient sample (n ϭ 5), or hospital discharge (n ϭ 3). Over time, arginine, citrulline, ornithine, and ADMA levels increased in both survivors and nonsurvivors, whereas SDMA levels did not change (Table 4) . At measurement 2, ornithine, ADMA, and SDMA were significantly higher in nonsurvivors compared to survivors. The arginine-to-DMA ratio increased over time in survivors but did not change significantly in nonsurvivors and remained lower in nonsurvivors vs. survivors at measurement 2 (Fig. 4) . These results suggest improving systemic Arg, arginine. a Values refer to median (interquartile range). Amino acid concentrations are micromolar, methylarginine concentrations are nanomolar, and methylarginine concentrations were converted to micromolar before calculation of the Arg/DMA ratio; b samples for measurement 1 were obtained 30 (20 -39) hrs after diagnosis; c samples for measurement 2 were obtained 67 (48 -72) hrs after measurement 1 and 90 (79 -110) hrs after diagnosis; d p Ͻ .001 compared to corresponding measurement 2 value in hospital survivors; e p Ͻ .01 compared to corresponding measurement 2 value in hospital survivors. arginine availability in the survivors but persistent impairment in the nonsurvivors. Whereas the arginine(citrulline ϩ ornithine) ratio did not change significantly over time in either survivors or nonsurvivors, the ratio remained lower in nonsurvivors vs. survivors at measurement 2 ( Table 4 ). The arginine-toornithine ratio, with lower values suggesting higher arginase activity, trended upward in survivors but downward in nonsurvivors, such that this ratio was significantly lower in nonsurvivors vs. survivors at measurement 2 ( Table 4 ).
DISCUSSION
The main finding of our study is that the ratio of arginine to its endogenous metabolic inhibitors, ADMA and SDMA, is associated with severe sepsis and severity of illness and independently predicts both hospital mortality and risk of death over the course of 6 months after diagnosis.
Our results indicate that this estimate of systemic arginine availability for NO synthesis could be a prognostically useful and pathophysiologically significant biomarker in severe sepsis, with potential therapeutic implications. Similar measurements and ratios have been calculated to estimate systemic arginine availability in a variety of cardiopulmonary disorders (5, 6, 25, 26) but, to our knowledge, such estimates have not been reported in septic patients.
The relationship between lower arginine-to-DMA ratio and higher mortality suggests that impaired capacity for NO synthesis is a clinically relevant and detrimental feature of sepsis pathophysiology. This concept is supported by the direct correlation between arginine-to-DMA ratio and urine nitrate shown in our post hoc analysis and previous experimental studies. For example, Mittermayer et al (14) showed that arginine and the arginine-to-ADMA ratio decline within 4 hrs of intravenous endotoxin in humans. Human endothelial cells exposed to lipopolysaccharide and tumor necrosis factor-␣ in vitro develop increased arginase activity and decreased endothelial NOS activity, suggesting diversion of arginine away from NO production (27) . Similar experiments showed that tumor necrosis factor-␣ decreases endothelial dimethyl-aminohydrolase activity, the enzyme responsible for ADMA breakdown, resulting in higher ADMA concentrations (28) . The hemodynamic consequences of these biochemical perturbations has been shown in rats treated with arginase (diverting arginine away from NO synthesis) and ADMA (blocking NO synthesis), causing decreased cardiac output, increased systemic vascular resistance, and decreased blood flow to liver, kidneys, and spleen (15) . Additional detrimental effects of low systemic arginine availability may include immune defi-ciency, impaired wound healing, and oxidative stress (29, 30) .
We found that arginine levels are lower in sepsis patients than in healthy subjects, consistent with several previous studies (7, 31) . Previous kinetic studies show that arginine decrements in sepsis are related to both impaired production (8) and accelerated clearance (10) . Importantly, enhanced arginine clearance appears to result from enhanced protein synthesis in sepsis (9) , not augmented NO production (8, 9) . Like our study, none of these articles reports a significant relationship between arginine concentration and severity of illness or outcome.
ADMA levels have been associated with severity of illness in septic patients (13) and poor outcome in unselected critically ill patients (11, 12) . Previous measurements of ADMA and SDMA in critical illness have used either an enzyme-linked immunoassay or high-performance liquid chromatography. To our knowledge, our study is the first to measure methylarginines using high-performance liquid chromatography coupled with mass spectrometry in sepsis. This method has significant advantages in separating and specifically quantifying ADMA and SDMA (32) .
Unlike ADMA, SDMA does not inhibit NOS (2) . Until recently, SDMA was thought to have little role in NO physiology and was largely ignored except as a novel measure of renal function (33) . However, recent studies show that SDMA inhibits NO synthesis and increases reactive oxygen species production in a dosedependent fashion in endothelial cells (3, 34) . The inhibitory effect of SDMA on NO production occurs through competitive inhibition of cellular arginine uptake via the cationic amino acid transporter system (4) . SDMA also independently predicts coronary artery disease severity, cardiovascular events, and dialysisassociated hypotension (35, 36) . These data show that SDMA is metabolically active and independently associated with cardiovascular disease. Importantly, the association we observed between the arginine-to-DMA ratio and mortality persisted after controlling for serum creatinine concentration.
We found that the arginine/(citrulline ϩ ornithine) ratio was similar in sepsis patients vs. controls. Whereas this estimate of systemic arginine availability was lower in nonsurvivors compared to survivors, it was not an independent predictor of outcomes in multivariable analysis. This ratio of reactant (arginine) to enzymatic products (citrulline and ornithine) has been used previously to estimate systemic arginine availability, because a lower ratio should reflect lower reactant availability. However, citrulline is metabolized back to arginine under physiologic conditions (9, 37) . This inter-conversion between product and reactant probably undermines the ability of this ratio to estimate systemic arginine availability.
Another limitation of the arginine/ (citrulline ϩ ornithine) ratio is that it will not reflect diversion of arginine metabolism from NOS to arginase, because products of both enzymes are in the denominator. Notably, ornithine was the only amino acid significantly different in nonsurvivors vs. survivors at measurement 2 (higher in nonsurvivors). The arginine-to-ornithine ratio previously has been validated as an estimate of arginase activity (6) . Although there was no difference in this ratio at the first measurement, the increasing ornithine concentration was greater over time in the nonsurvivors, resulting in a lower arginine-to-ornithine ratio in nonsurvivors vs. survivors at measurement 2. These results suggest a link between arginase activity and worsening sepsis pathophysiology in nonsurvivors.
The therapeutic implications of our findings are worthy of consideration. Arginine supplementation has been studied in critically ill patients with mixed and controversial results (29, 37, 38) , with some studies suggesting harm, particularly in patients with severe sepsis (39, 40) . Although these clinical trials are limited by co-administration of several immunonutrients, insufficient power, and methodologic weaknesses (37), they are supported by experimental sepsis studies showing that arginine therapy is harmful (41) . Published nutritional guidelines recommend against arginine supplementation in critically ill septic patients (42) .
Our results confirm low arginine levels in severe sepsis but indicate that outcomes are predicted only by the arginineto-DMA ratio. Furthermore, although we found that arginine levels increase over time during the course of sepsis, the arginine-to-DMA ratio remains low in nonsurvivors, whereas it improves in survivors. These findings suggest the potential for novel therapeutic interventions that could specifically increase systemic arginine availability in severe sepsis, without administering exogenous arginine. For example, oxidative stress decreases di-methyl-aminohydrolase activity, slows ADMA clearance, and increases ADMA production (43, 44) . These effects are prevented by antioxidant therapy. Antioxidant therapy has been studied in sepsis and a compilation of the evidence suggests benefit (45) . The arginine-to-DMA ratio could be used to specifically identify patients for enrollment in clinical trials of antioxidant therapy. Sepsis is a heterogeneous syndrome, and biomarkerbased identification of patients eligible for tailored therapies offers promise (1) . In addition, the declining arginine-toornithine ratio in nonsurvivors could warrant consideration of arginase inhibition as a novel therapeutic strategy that could be offered later in the course of sepsis (46) .
Study Limitations
Our study shares the limitation of all observational research in that it determines associations, not causality. Therefore, the possible detrimental effects of low arginine-to-DMA ratio discussed herein are speculative and must be further evaluated.
It is important to emphasize that the arginine-to-DMA ratio only estimates systemic arginine availability. The arginineto-DMA ratio does not include monomethylarginine, another protein arginine methyltransferase-catalyzed arginine metabolite that inhibits NOS (2), and was included in the denominator of the ratio reported by Lara et al (5) . However, monomethylarginine concentrations are approximately one-tenth those of either ADMA or SDMA, so its exclusion only has a small effect on the magnitude of the ratio. The arginine-to-DMA ratio also does not provide precise insights about the metabolic fate of arginine in severe sepsis. The latter requires isotope studies that were beyond the scope of this study. However, such studies have been performed previously in smaller cohorts and support the concept that arginine bioavailability and NO production are reduced in sepsis (8, 10) . Likewise, we also could not determine whether DMA concentrations were correlated with the extent of protein breakdown because we did not measure nitrogen balance or other indices of protein catabolism.
It is also important to note that urine nitrate concentrations only approximately estimate systemic NO production (47) . We were unable to determine which of the NOS isoforms were most active in our septic patients or whether they may have been affected differently by altered concentrations of arginine and its metabolites. In addition, the urine nitrate measurements were performed post hoc, so these findings serve only to generate hypotheses and require further study.
Finally, because we chose a relatively healthy control group, we cannot rule out the possibility that our findings are applicable to nonseptic critically ill subjects. This healthy control group was necessary to establish expected ranges of arginine metabolites in subjects with age and gender distributions similar to those of our severe sepsis patients. The possibility that the arginine-to-DMA ratio is a useful predictor of illness severity and outcomes in nonseptic critically ill patients warrants additional study.
CONCLUSIONS
The arginine-to-DMA ratio is reduced in severe sepsis and associated with illness severity. A low arginine-to-DMA ratio independently predicts higher hospital mortality and lower 6-month survival. Novel interventions that augment systemic arginine availability but do not require arginine supplementation should be studied in severe sepsis.
